Cargando…

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?

Detalles Bibliográficos
Autores principales:	Laster, Andrew J, Lam, Gordon K, Gladue, Heather S, Kashif, Ahmad A, Siceloff, Erin P, Lackey, Virginia D, Robertson, Cheryl R, Toci, Ashley L, Calabrese, Leonard H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Infections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086281/ https://www.ncbi.nlm.nih.gov/pubmed/35534054 http://dx.doi.org/10.1136/rmdopen-2022-002203

Ejemplares similares

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD
por: Furer, Victoria, et al.
Publicado: (2019)

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations
por: Jansen, Marc H., et al.
Publicado: (2022)

Exercise, infection and rheumatic diseases: what do we know?
por: Calabrese, Leonard, et al.
Publicado: (2021)

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: DiIorio, Michael, et al.
Publicado: (2022)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases
por: McMahan, Zsuzsanna H, et al.
Publicado: (2014)

Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy
por: Vanni, Kathleen MM, et al.
Publicado: (2022)

Development of Autoantibodies Following BNT162b2 mRNA COVID-19 Vaccination and Their Association with Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population: Results of 1-Year Prospective Follow-Up Study
por: Gazitt, Tal, et al.
Publicado: (2023)

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021)

Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
por: Zheng, Yi-Qing, et al.
Publicado: (2022)

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
por: Álvaro Gracia, Jose María, et al.
Publicado: (2021)

Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Facilitators and barriers of vaccine uptake in patients with autoimune inflammatory rheumatic disease: a scoping review
por: Neusser, Silke, et al.
Publicado: (2022)

Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
por: Andreica, Ioana, et al.
Publicado: (2023)

Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases
por: Tonacio, Adriana Coracini, et al.
Publicado: (2021)

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity
por: Calabrese, Cassandra, et al.
Publicado: (2022)

Maternal and neonatal antibody levels on pertussis vaccination in pregnant women on immune-modulating therapy for rheumatic disease
por: Ghalandari, Nafise, et al.
Publicado: (2023)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
por: Raptis, Catherine E., et al.
Publicado: (2022)

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study
por: Kiltz, Uta, et al.
Publicado: (2021)

Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up
por: Naovarat, Benjamin Sornrung, et al.
Publicado: (2022)

Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider
por: Alunno, Alessia, et al.
Publicado: (2021)

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
por: Schulze-Koops, Hendrik, et al.
Publicado: (2021)

Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases
por: Emi Aikawa, Nádia, et al.
Publicado: (2021)

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
por: Sieiro Santos, Cristiana, et al.
Publicado: (2022)

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases
por: Hasseli, Rebecca, et al.
Publicado: (2021)

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
por: Hasseli, Rebecca, et al.
Publicado: (2023)

Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1)
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: Sattui, Sebastian Eduardo, et al.
Publicado: (2021)

A novel immunomodulatory function of neutrophils on rhinovirus-activated monocytes in vitro
por: Tang, Francesca S M, et al.
Publicado: (2016)

Autoimmune Rheumatic Diseases
por: Anaya, Juan-Manuel, et al.
Publicado: (2014)

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
por: Marques, Claudia Diniz Lopes, et al.
Publicado: (2021)

Anxiety and concerns related to the work situation during the second wave of the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the DANBIO registry
por: Glintborg, Bente, et al.
Publicado: (2021)

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
por: Liew, Jean, et al.
Publicado: (2022)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
por: Neuhaus, Vanessa, et al.
Publicado: (2018)

LONG-TERM CONSEQUENCES OF COVID-19 AMONG PATIENTS WITH RHEUMATIC DISEASES
por: BEKETOVA, TATIANA, et al.
Publicado: (2021)

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
por: Davda, Jasmine, et al.
Publicado: (2019)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
por: Lawson-Tovey, Saskia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m7ve3fh42kpeo3bn2c6smfamf3